Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28458792 | 1.00 | KCNH2 (0.36) | KCNH2SSTR4AAK1MAPTPKM | |
| SCHEMBL22684294 | 0.95 | KCNH2 (0.35) | KCNH2SSTR4AAK1 | |
| SCHEMBL19776245 | 0.84 | KCNH2 (0.35) | KCNH2SSTR4MAPTALDH1A1LMNA | |
| SCHEMBL21459919 | 0.80 | KCNH2 (0.34) | KCNH2SSTR4ALDH1A1 | |
| SCHEMBL29835592 | 0.79 | NR1D1 (0.33) | MAPTALDH1A1LMNA | |
| SCHEMBL18146098 | 0.79 | NR1D1 (0.33) | MAPTALDH1A1LMNA | |
| SCHEMBL29835598 | 0.79 | NR1D1 (0.33) | MAPTALDH1A1LMNA | |
| SCHEMBL20045607 | 0.79 | MAPT (0.34) | KCNH2SSTR4MAPTALDH1A1LMNA | |
| SCHEMBL30059621 | 0.79 | SSTR4 (0.39) | KCNH2SSTR4MAPTALDH1A1LMNA | |
| SCHEMBL26919345 | 0.76 | NR1D1 (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | KCNH2 2677/4885SSTR4 4193/4885AAK1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.